

## Drug and Therapeutics Committee – Minutes

<b>Date / Time</b>	June 9 <sup>th</sup> 2022
<b>Venue</b>	WebEx
<b>Chair</b>	Prof A Morice, Chair, Professor of Respiratory Medicine
<b>Notes / Action Points</b>	
<b>Quorate: Yes / No</b>	Yes

<b>Attendance</b>	Prof M Lind, Vice Chair, Professor of Oncology, HUTH Mr K McCorry, Medicines Optimisation Pharmacist, NECS Miss J Morgan, Professional Secretary, Principal Pharmacist – Formulary HUTH Dr O Ogunbambi, Consultant Rheumatologist, HUTH Ms J Goode, Chief Pharmacist, HUTH Dr S Raise, GP Prescribing Lead, ER CCG Dr B Ali, GP Prescribing Lead, Hull CCG Dr A Dawood, Consultant Anaesthetist, HUTH Mr P O'Brien, Deputy Chief Pharmacist, HUTH
-------------------	---

<b>Apologies</b>	Mr R Kapur, Consultant Vascular Surgeon, HUTH Dr A Samson, Consultant Infectious Diseases, HUTH Dr H Klonin, Consultant Paediatrician, HUTH
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2022.06.01	<b>Apologies</b>	As Above.					
2022.06.02	<b>Declarations of Interest</b>	None					
2022.06.03	<b>Minutes of the previous meeting</b>	Accepted as an accurate record	no action required				
2022.06.04	<b>Action Tracker</b>	<p><b>Dissemination of Information Across All Healthcare Groups /Providers</b> JM updated on this - in last 12 months have sent 2 items from the MHRA DSU for specific specialities via specialist pharmacists and their speciality governance. Both of these where paediatric and they looked at and responded to the alert. To continue disseminating via this route for alerts for specific specialities/</p> <p><b>Hydroxychloroquine in RA</b> JM discussed with rheumatology business manager and sending pathway. Awaiting discussion with Ophthalmology business manager</p> <p><b>ARIA forms – Zoledronic acid</b> Guidance going through multiple speciality and health group governance at moment.</p> <p><b>New Product Requests</b> JM to request feedback from Dr Jose about clonidine patches in 6 months</p> <p><b>NICE Guidance</b> JM to confirm with neurology about TAs 748 and 758 -JM emailed Dr Ming, will apply for TA748. -JM to have meeting with neurology about TA758 Narcolepsy pathway JM not met with Dr Ming/Dr Goorah yet</p> <p><b>New Product Requests</b> AM to write to applicants</p>	<p>Action complete</p> <p>JM to contact business manager</p> <p>For D&amp;T when been to speciality governance</p> <p>Feedback in Sept 22</p> <p>Update next time</p> <p>Action complete</p>	<p>Complete</p> <p>Ongoing</p> <p>Add to agenda</p> <p>Ongoing</p> <p>Ongoing</p> <p>Complete</p>	<p>JM</p> <p>JM</p> <p>LS</p> <p>JM</p> <p>JM</p> <p>AM</p>	<p></p> <p>5/22</p> <p>9/22</p> <p>9/22</p> <p>5/22</p> <p></p>	<p>6/22</p> <p></p> <p></p> <p></p> <p></p> <p>6/22</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p><b>NICE Guidance</b> LS to update back of formulary</p>	Action complete	Complete	LS		6/22
		<p><b>NICE Guidance</b> JM to check aria forms</p>	Action complete	Complete	JM		6/22
		<p><b>Clinical guidelines – Biologics and small molecules for IBD</b> JM has met with Prof Sebastian and discussed updating guideline and audit. The advanced clinical pharmacist for gastro is now attending IBD MDT and will pick an audit after attending sufficient MDTs. New action: To add guidance on agenda when updated.</p>	Action complete	Complete	JM		6/22
		<p><b>NICE Guidance</b> JM to check with Dr Gordins regarding TA769. E-mailed Dr Gordins with no response.</p>	Ongoing	To update next time	JM		
		<p><b>NICE Guidance</b> JM to inform renal about approval of TA775. E-mailed Prof Bhandari and renal will use for this indication.</p>	Action complete	Complete			6/22
		<p><b>NICE Guidance</b> JM to contact ENT about new product in guidance. Contacted Mrs Pearson who says they would not use the new product (local anaesthetic plus anti-inflammatory). However, would be appropriate to use in primary care, JM in process of updating primary care guidance.</p>	Action complete	Complete			6/22

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2022.06.05	New Product Requests	<p><b>New Product Requests:</b></p> <ul style="list-style-type: none"> <li>Saciztuzumab govitecan- Approved. Manufacturer free of charge scheme available for this product; this scheme fulfils RMOG guidance and NICE is in progress.</li> <li>Berotrastat – approved as per NICE TA738</li> </ul> <p><b>ARIA Forms:</b></p> <ul style="list-style-type: none"> <li>Mogamulizumab (TA754)</li> <li>Tucatinib, capecitabine, trastuzumab (TA786)</li> </ul>	<p>Approved</p> <p>Approved as per TA Approved as per TA</p>	JM to inform consultants LS to update formulary	JM/LS	6/22	
2022.06.06	NICE guidance	<p><b>Nice Guidance April 2022</b></p> <ul style="list-style-type: none"> <li><b>TA783</b> Daratumumab monotherapy for treating relapsed and refractory multiple myeloma</li> <li><b>NG128</b> Stroke and transient ischaemic attack in over 16s: diagnosis and initial management</li> <li><b>NG191</b> COVID-19 rapid guideline: managing COVID-19</li> <li><b>NG215</b> Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults</li> <li><b>TA785</b> Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)</li> <li><b>TA784</b> Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer</li> <li><b>NG217</b> Epilepsies in children, young people and adults</li> <li><b>TA787</b> Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable</li> <li><b>TA786</b> Tucatinib with trastuzumab and capecitabine for treating HER2-positive</li> </ul>	<p>ARIA form needed</p> <p>Noted</p> <p>Noted</p> <p>Noted</p> <p>Terminated appraisal</p> <p>ARIA form needed</p> <p>Replaces older CG137, no changes ARIA form needed</p> <p>Discussed on agenda</p>	<p>No action required</p> <p>No action required</p> <p>No action required</p> <p>No action required</p> <p>No action required</p> <p>No action required</p> <p>No action required</p> <p>No action required</p>			

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>advanced breast cancer after 2 or more anti-HER2 therapies</p> <p><b>May 2022</b></p> <ul style="list-style-type: none"> <li>• <b>TA788</b> Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy</li> <li>• <b>NG218</b> Vaccine uptake in the general population</li> <li>• <b>TA789</b> Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations</li> <li>• <b>NG191</b> COVID-19 rapid guideline: managing COVID-19</li> <li>• <b>TA791</b> Romosozumab for treating severe osteoporosis</li> <li>• <b>TA790</b> TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal)</li> <li>• <b>NG216</b> Social work with adults experiencing complex needs</li> <li>• <b>HST205</b> Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over</li> </ul>	<p>ARIA form needed</p> <p>Noted</p> <p>Noted</p> <p>Noted</p> <p>New- application request required</p> <p>Terminated appraisal</p> <p>Noted</p> <p>Potentially not HUTH</p>	<p>No action required</p> <p>No action required</p> <p>No action required</p> <p>No action required</p> <p>Request application from metabolic bone</p> <p>No action required</p> <p>No action required</p> <p>No action required</p>	JM	7/22	
2022.06.07	<b>MHRA Drug safety update</b>	<ul style="list-style-type: none"> <li>• <a href="#">April 2022</a></li> <li>• Pregabalin (Lyrica): findings of safety study on risks during pregnancy- this article was noted and to ask Mr Sedman to include in consultants newsletter.</li> <li>• <a href="#">May 2022</a></li> <li>• Denosumab should not be used in anyone under age of 18</li> </ul>					06/22
2022.06.08	<b>Minutes of the Safe Medication Practice Committee</b>	Nil this month	Complete	No action required			

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2022.06.09	<b>Minutes from the Hull and East Riding Prescribing Committee</b>	March 2022- Contents noted	Complete	No action required			
2022.06.10	<b>Regional Medicines Optimisation Committee</b>	Nil this month					
2022.06.11	<b>Clinical guidelines</b>	Nil this month					
2022.06.12	<b>Correspondence received</b>	<ul style="list-style-type: none"> <li>National Patient Safety Alert – Potassium Permanganate</li> </ul>	Further info required	To contact dermatology and confirm they still require	JM	7/22	
2022.06.13	<b>Chairs Approvals</b>	<ul style="list-style-type: none"> <li>Oxandrolone- Dr K. Tharian- Growth stimulation</li> <li>Sacituzumab – Dr Dhadda – triple negative breast cancer</li> </ul>	Approved Approved	No action required			
2022.06.14	<b>Issues to escalate to P&amp;CE</b>	Nil	Complete	No action required			
2022.06.15	<b>Any Other Business</b>	<ul style="list-style-type: none"> <li>Andexanet- Discussed points on need of item and potential use against cost. Dr Nelson to write potential guidance</li> <li>Smallpox vaccine- small supply for use in monkey pox. To update formulary.</li> </ul>					
2022.06.16	<b>Date and Time of Next Meeting</b>	11 <sup>th</sup> August 2022 8:15 am					